FDA Removes Breast Cancer, Heart and Dementia Boxed Warnings From 3 More Estrogen Patches Amid Supply Strain

The Food and Drug Administration on Thursday approved new labeling for three more estrogen patches used to treat menopause symptoms, removing statements about cardiovascular disease, breast cancer and probable dementia from the products’ boxed warnings, the agency’s most prominent safety alert.

The action, announced Oct. 30 by the Department of Health and Human Services, extends a relabeling effort that began with six hormone therapy products in February. It came with an update on a problem some women have run into at the pharmacy counter: estradiol patches that are hard to find as demand has climbed.

“Removing outdated statements from these boxed warnings marks a major victory for women’s health,” Health Secretary Robert F. Kennedy Jr. said in the announcement.

Which menopause products got new labels?

HHS said the FDA approved updated labeling for three estradiol transdermal patches from two drug companies. The FDA’s list of menopausal hormone therapies with updated prescribing information, revised Oct. 30, now names nine products, including three patches: Minivelle, Vivelle and Vivelle-Dot.

The other six on the list were approved in February 2026, when the FDA cleared the first batch of label changes. That group, covering all four types of menopausal hormone therapy, includes Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva.

The FDA first asked manufacturers to submit label revisions in November 2025. HHS said 29 drug companies have now submitted proposed changes, and the agency is “working expeditiously” to act on the rest.

Why is the FDA changing the warnings?

HHS said the changes reflect “a thorough re-examination of the scientific literature” and updated information on the benefits and risks of these drugs. In February, the FDA said randomized studies show that women who start hormone therapy within 10 years of the onset of menopause, generally before age 60, have lower rates of death from all causes and fewer fractures.

The agency also said few women who might benefit use these treatments: about 41 million U.S. women were ages 45 to 64 in 2020, the FDA said, but only about 2 million women ages 46 to 65 received a hormone therapy prescription.

Thursday’s action supports an executive order, Advancing Women’s Health to Improve Outcomes in All Phases of Life, that President Trump signed on Oct. 19, HHS said. “We are equally committed to ensuring that when women and their doctors determine hormone therapy is right for them, they can access it,” Acting FDA Commissioner Kyle Diamantas said.

Is there a shortage of estrogen patches?

Not nationwide, according to the FDA. The agency said it is in close contact with makers of every FDA-approved menopausal hormone therapy and “is not aware of an imminent risk of a nationwide shortage.”

But the FDA acknowledged local problems. It said it has heard from patients who could not find their usual products and is working with all six manufacturers of FDA-approved estradiol patches on access challenges “driven by a significant rise in demand.” Manufacturers have added production capacity and shifts and are prioritizing patch output, which HHS said has doubled overall market output in the last 12 months.

In a September update, the FDA tied the jump in demand to its November 2025 request to remove the warnings and said larger expansions take time because patches need specialized equipment.

What else is the FDA doing to expand access?

HHS described three other steps:

• Compounding: estradiol and estradiol-containing combinations are listed as Category 1 bulk drug substances under the FDA’s interim policy for 503B outsourcing facilities. That means the FDA does not intend to take action against those facilities for compounding with them, as long as certain conditions are met. Traditional 503A pharmacy compounding also remains available with a valid prescription for an individual patient.
• Generics: the FDA pointed to its approvals of generic menopausal hormone therapies, including a once-weekly generic patch.
• Over-the-counter vaginal estrogen: the FDA is working with drug sponsors to explore whether vaginal estrogen products could be sold without a prescription. Any switch would need FDA approval, backed by evidence that consumers can choose and use the product safely without a clinician’s supervision.

What should women do if they can’t find their patch?

The FDA’s advice is to start with the pharmacist, who may be able to locate another FDA-approved estradiol patch that can be substituted when appropriate. Availability can vary by brand, strength, location and whether a patch is changed once or twice a week, the agency said.

If the usual patch is not available, the FDA says to ask your health care provider about other options, including other estradiol products such as gels and creams. The key caution: do not stop or change your medication without talking to your provider first, and check back with the pharmacy, because supply may improve as more product ships.

The label changes do not mean hormone therapy is right for everyone. The FDA encourages women to talk with their providers about the potential benefits and risks for their own health. The news follows another FDA action this week, a proposed update to infant formula nutrient requirements.

Key Takeaways

• The FDA approved new labels for three more estradiol patches, removing cardiovascular disease, breast cancer and probable dementia statements from their boxed warnings.
• Nine menopause hormone therapy products now carry the updated labels, and 29 companies have submitted proposed changes.
• The FDA says it sees no imminent nationwide shortage, but some women still can’t find their usual patch; output has doubled in a year.
• If your patch is out of stock, ask your pharmacist about an equivalent, and don’t stop or switch without talking to your provider.

Frequently Asked Questions

Featured image: A box of Vivelle-Dot estradiol patches, one of the three products with updated labeling. Illustrative photo. (Photo by Belinda Hankins Miller, CC BY 2.0, via Wikimedia Commons)